Preventing ARDS: Progress, promise, and pitfalls

Chest

Volumn 146, Issue 4, 2014, Pages 1102-1113

  Beitler, Jeremy R ^a   Schoenfeld, David A ^b   Taylor Thompson, B ^b  

^a Brigham and Women's Hospital   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; COLECALCIFEROL; CORTICOSTEROID; DIPYRIDAMOLE; KETOCONAZOLE; PLACEBO; RECOMBINANT KERATINOCYTE GROWTH FACTOR; SALMETEROL;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; BODY POSITION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FUNCTIONAL STATUS; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; LOW TIDAL VOLUME VENTILATION; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; NOSOCOMIAL PNEUMONIA; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; RISK REDUCTION; SEPSIS; STUDY DESIGN; INCIDENCE; LUNG INJURY; PROCEDURES; RESPIRATORY DISTRESS SYNDROME, ADULT;

CRITICAL CARE; HUMANS; INCIDENCE; LUNG INJURY; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84907938084     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0555     Document Type: Article

References (98)

1. Li G, Malinchoc M, Cartin-Ceba R, et al. Eight-year trend of acute respiratory distress syndrome: A population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med. 2011; 183 ( 1 ): 59 - 66.
2. Ciesla DJ, Moore EE, Johnson JL, et al. Decreased progression of postinjury lung dysfunction to the acute respiratory distress syndrome and multiple organ failure. Surgery. 2006; 140 ( 4 ): 640 - 647.
3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342 ( 18 ): 1301 - 1308.
4. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: A meta-analysis. JAMA. 2012; 308 ( 16 ): 1651 - 1659.
5. Futier E, Constantin JM, Paugam-Burtz C, et al; IMPROVE Study Group. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med. 2013; 369 ( 5 ): 428 - 437.
6. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345 ( 19 ): 1368 - 1377.
7. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34 ( 6 ): 1589 - 1596.
8. Hébert PC, Wells G, Blajchman MA, et al; Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999; 340 ( 6 ): 409 - 417.
9. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: Prospective nested case-control study. Am J Respir Crit Care Med. 2007; 176 ( 9 ): 886 - 891.
10. Rosenthal VD, Rodrigues C, Álvarez-Moreno C, et al; INICC members. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents: findings of the International Nosocomial Infection Control Consortium. Crit Care Med. 2012; 40 ( 12 ): 3121 - 3128.
11. Ranieri VM, Rubenfeld GD, Thompson BT, et al; ARDS Definition Task Force. Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012; 307 ( 23 ): 2526 - 2533.
12. Gajic O, Dabbagh O, Park PK, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS). Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2011; 183 ( 4 ): 462 - 470.
13. Levitt JE, Calfee CS, Goldstein BA, Vojnik R, Matthay MA. Early acute lung injury: criteria for identifying lung injury prior to the need for positive pressure ventilation. Crit Care Med. 2013; 41 ( 8 ): 1929 - 1937.
14. Herridge MS, Tansey CM, Matté A, et al; Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011; 364 ( 14 ): 1293 - 1304.
15. Fan E, Dowdy DW, Colantuoni E, et al. Physical complications in acute lung injury survivors: A two-year longitudinal prospective study. Crit Care Med. 2014; 42 ( 4 ): 849 - 859.
16. Hejblum G, Chalumeau-Lemoine L, Ioos V, et al. Comparison of routine and on-demand prescription of chest radiographs in mechanically ventilated adults: A multicentre, cluster-randomised, two-period crossover study. Lancet. 2009; 374 ( 9702 ): 1687 - 1693.
17. Pilon CS, Leathley M, London R, et al. Practice guideline for arterial blood gas measurement in the intensive care unit decreases numbers and increases appropriateness of tests. Crit Care Med. 1997; 25 ( 8 ): 1308 - 1313.
18. Wiedemann HP, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med. 2006; 354 ( 24 ): 2564 - 2575.
19. Mekontso Dessap A, Katsahian S, Roche-Campo F, et al. Ventilatorassociated pneumonia during weaning from mechanical ventilation: role of fl uid management. Chest. 2014;146(1):58-65.
20. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013; 369 ( 22 ): 2126 - 2136.
21. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA. 1999; 282 ( 1 ): 54 - 61.
22. Imai Y, Parodo J, Kajikawa O, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA. 2003; 289 ( 16 ): 2104 - 2112.
23. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 295 ( 3 ): L379 - L399.
24. Gajic O, Dara SI, Mendez JL, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med. 2004; 32 ( 9 ): 1817 - 1824.
25. Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A. Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med. 2005; 31 ( 7 ): 922 - 926.
26. Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: A preventive randomized controlled trial. Crit Care. 2010; 14 ( 1 ): R1.
27. Ferguson ND. Low tidal volumes for all? JAMA. 2012; 308 ( 16 ): 1689 - 1690.
28. Bramley AM, Dasgupta S, Skarbinski J, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Intensive care unit patients with 2009 pandemic infl uenza A (H1N1pdm09) virus infection - United States, 2009. Influenza Other Respi Viruses. 2012; 6 ( 6 ): e134 - e142.
29. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med. 2014; 2 ( 5 ): 395 - 404.
30. Iscimen R, Cartin-Ceba R, Yilmaz M, et al. Risk factors for the development of acute lung injury in patients with septic shock: An observational cohort study. Crit Care Med. 2008; 36 ( 5 ): 1518 - 1522.
31. Puskarich MA, Trzeciak S, Shapiro NI, et al; Emergency Medicine Shock Research Network (EMSHOCKNET). Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med. 2011; 39 ( 9 ): 2066 - 2071.
32. Yilmaz M, Keegan MT, Iscimen R, et al. Toward the prevention of acute lung injury: Protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med. 2007; 35 ( 7 ): 1660 - 1666.
33. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007; 131 ( 5 ): 1308 - 1314.
34. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009; 119 ( 11 ): 3450 - 3461.
35. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007; 35 ( 7 ): 1645 - 1648.
36. Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion. 2010; 50 ( 6 ): 1312 - 1321.
37. Ahmed AH, Litell JM, Malinchoc M, et al. The role of potentially preventable hospital exposures in the development of acute respiratory distress syndrome: A population-based study. Crit Care Med. 2014; 42 ( 1 ): 31 - 39.
38. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogué S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet. 1999; 354 ( 9193 ): 1851 - 1858.
39. Kor DJ, Talmor DS, Banner-Goodspeed VM, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A). Lung Injury Prevention with Aspirin (LIPS-A): A protocol for a multicentre randomized clinical trial in medical patients at high risk of acute lung injury. BMJ Open. 2012; 2 ( 5 ): e001606.
40. Ferguson ND, Frutos-Vivar F, Esteban A, et al. Clinical risk conditions for acute lung injury in the intensive care unit and hospital ward: A prospective observational study. Crit Care. 2007; 11 ( 5 ): R96.
41. Festic E, Bansal V, Kor DJ, Gajic O, US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS). SpO2/FiO2 ratio on hospital admission is an indicator of early acute respiratory distress syndrome development among patients at risk [published online ahead of print December 20, 2013]. J Intensive Care Med. doi:10.1177/08850666136516411.
42. Agrawal A, Zhuo H, Brady S, et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol. 2012; 303 ( 8 ): L634 - L639.
43. Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld ABJ. Plasma biomarkers for acute respiratory distress syndrome: A systematic review and meta-analysis. Crit Care Med. 2014; 42 ( 3 ): 691 - 700.
44. Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma. 2010; 68 ( 5 ): 1121 - 1127.
45. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care. 2013; 17 ( 5 ): R253.
46. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med. 2013; 187 ( 7 ): 736 - 742.
47. Gao L, Barnes KC. Recent advances in genetic predisposition to clinical acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2009; 296 ( 5 ): L713 - L725.
48. Tejera P, Meyer NJ, Chen F, et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet. 2012; 49 ( 11 ): 671 - 680.
49. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995; 151 ( 2 ): 293 - 301.
50. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC. Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion. Crit Care Med. 2005; 33 ( 6 ): 1191 - 1198.
51. Levitt JE, Bedi H, Calfee CS, Gould MK, Matthay MA. Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure. Chest. 2009; 135 ( 4 ): 936 - 943.
52. Pickering BW, Gajic O, Ahmed A, Herasevich V, Keegan MT. Data utilization for medical decision making at the time of patient admission to ICU. Crit Care Med. 2013; 41 ( 6 ): 1502 - 1510.
53. Levitt JE, Matthay MA. Clinical review: early treatment of acute lung injury - paradigm shift toward prevention and treatment prior to respiratory failure. Crit Care. 2012; 16 ( 3 ): 223.
54. Weigelt JA, Norcross JF, Borman KR, Snyder WH III. Early steroid therapy for respiratory failure. Arch Surg. 1985; 120 ( 5 ): 536 - 540.
55. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988; 138 ( 1 ): 62 - 68.
56. Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care. 1999; 14 ( 1 ): 1 - 6.
57. Vincent JL, Brimioulle S, Berre J, Kahn RJ. Prevention of the adult respiratory distress syndrome with dipyridamole. Crit Care Med. 1985; 13 ( 10 ): 783 - 785.
58. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front Biosci (Landmark Ed). 2009; 14 : 150 - 158.
59. Kiefmann R, Heckel K, Schenkat S, Dörger M, Wesierska-Gadek J, Goetz AE. Platelet-endothelial cell interaction in pulmonary micro-circulation: The role of PARS. Thromb Haemost. 2004; 91 ( 4 ): 761 - 770.
60. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006; 116 ( 12 ): 3211 - 3219.
61. Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest. 2011; 139 ( 2 ): 289 - 295.
62. El-Kebir D, József L, Pan W, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med. 2009; 180 ( 4 ): 311 - 319.
63. Kor DJ, Erlich J, Gong MN, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investi gators (USCIITG-LIPS). Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med. 2011; 39 ( 11 ): 2393 - 2400.
64. Gajic O, Gong MN, Talmor D. LIPS-A: Lung injury prevention study with aspirin. NCT01504867. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT01504867. Bethesda, MD: National Institutes of Health; 2012. Updated March 17, 2014.
65. Jansson AH, Eriksson C, Wang X. Effects of budesonide and N-acetylcysteine on acute lung hyperinfl ation, infl ammation and injury in rats. Vascul Pharmacol. 2005; 43 ( 2 ): 101 - 111.
66. Wang J, Zhang L, Walther SM. Inhaled budesonide in experimental chlorine gas lung injury: Infl uence of time interval between injury and treatment. Intensive Care Med. 2002; 28 ( 3 ): 352 - 357.
67. Walther S, Jansson I, Berg S, Lennquist S. Pulmonary granulocyte accumulation is reduced by nebulized corticosteroid in septic pigs. Acta Anaesthesiol Scand. 1992; 36 ( 7 ): 651 - 655.
68. Walther S, Jansson I, Berg S, Olsson Rex L, Lennquist S. Corticosteroid by aerosol in septic pigs-effects on pulmonary function and oxygen transport. Intensive Care Med. 1993; 19( 3): 155- 160.
69. Ortiz-Diaz E, Li G, Kor DJ, et al. Preadmission use of inhaled corticosteroids is associated with a reduced risk of direct acute lung injury/acute respiratory distress syndrome. Chest. 2011; 140 ( 4-MeetingAbstracts ): 912.
70. Tang BMP, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. Crit Care Med. 2009; 37 ( 5 ): 1594 - 1603.
71. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: Meta-analysis. BMJ. 2008; 336 ( 7651 ): 1006 - 1009.
72. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001; 163( 6): 1376- 1383.
73. Folkesson HG, Matthay MA. Alveolar epithelial ion and fluid transport: recent progress. Am J Respir Cell Mol Biol. 2006; 35 ( 1 ): 10 - 19.
74. McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of b 2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med. 2004; 32 ( 7 ): 1470 - 1476.
75. Atabai K, Ware LB, Snider ME, et al. Aerosolized b (2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med. 2002; 28 ( 6 ): 705 - 711.
76. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002; 346 ( 21 ): 1631 - 1636.
77. Matthay MA, Brower RG, Carson S, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized b2 -agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011; 184 ( 5 ): 561 - 568.
78. Gao Smith F, Perkins GD, Gates S, et al; BALTI-2 Study Investigators. Effect of intravenous b -2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): A multicentre, randomised controlled trial. Lancet. 2012; 379 ( 9812 ): 229 - 235.
79. Perkins GD, Gates S, Park D, et al; BALTI-Prevention Collaborators. The beta agonist lung injury trial prevention: A randomized controlled trial. Am J Respir Crit Care Med. 2014; 189 ( 6 ): 674 - 683.
80. Festic E, Levitt JE. LIPS-B: Lung injury prevention study with budesonide and beta agonist (formoterol). NCT01783821. Clinical Trials.gov. http://www.clinicaltrials.gov/ct2/show/NCT01783821. Bethesda, MD: National Institutes of Health; 2013. Updated December 13, 2013.
81. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002; 282 ( 5 ): L924 - L940.
82. Brauchle M, Angermeyer K, Hübner G, Werner S. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene. 1994; 9 ( 11 ): 3199 - 3204.
83. Yano T, Deterding RR, Simonet WS, Shannon JM, Mason RJ. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol. 1996; 15 ( 4 ): 433 - 442.
84. Viget NB, Guery BP, Ader F, et al. Keratinocyte growth factor protects against Pseudomonas aeruginosa -induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2000; 279 ( 6 ): L1199 - L1209.
85. Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growth-factor promotes epithelial survival and resolution in a human model of lung injury [published online ahead of print April 9, 2014]. Am J Respir Crit Care Med. doi:10.1164/rccm.201310-1892OC.
86. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic eff ects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013; 187 ( 7 ): 751 - 760.
87. Cross LJM, O'Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction-a randomised placebo-controlled trial (KARE): study protocol. Trials. 2013; 14 : 51.
88. Albert RK. The role of ventilation-induced surfactant dysfunction and atelectasis in causing acute respiratory distress syndrome. Am J Respir Crit Care Med. 2012; 185 ( 7 ): 702 - 708.
89. Thickett D. Vitamin D replacement to prevent acute lung injury following oesophagectomy (VINDALOO). ISRCTN27673620. Controlled-Trials.com. http://www.controlled-trials.com/ISRCTN27673620. Birmingham, England: University of Birmingham; 2011. Updated December 21, 2011.
90. Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an effi cacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002; 30 ( 8 ): 1772 - 1777.
91. Willson DF, Thomas NJ, Markovitz BP, et al; Pediatric Acute Lung Injury and Sepsis Investigators. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: A randomized controlled trial. JAMA. 2005; 293 ( 4 ): 470 - 476.
92. Spragg RG, Bernard GR, Checkley W, et al. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med. 2010; 181 ( 10 ): 1121 - 1127.
93. Young P, Hodgson C, Dulhunty J, et al; ANZICS Clinical Trials Group. End points for phase II trials in intensive care: recommendations from the Australian and New Zealand Clinical Trials Group consensus panel meeting. Crit Care Resusc. 2012; 14 ( 3 ): 211 - 215.
94. Kahn JM, Benson NM, Appleby D, Carson SS, Iwashyna TJ. Long-term acute care hospital utilization after critical illness. JAMA. 2010; 303 ( 22 ): 2253 - 2259.
95. Lane-Fall MB, Iwashyna TJ, Cooke CR, Benson NM, Kahn JM. Insurance and racial differences in long-term acute care utilization after critical illness. Crit Care Med. 2012; 40 ( 4 ): 1143 - 1149.
96. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme JF Jr. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2005; 171 ( 4 ): 340 - 347.
97. Becker LB, Aufderheide TP, Geocadin RG, et al; American Heart Association Emergency Cardiovascular Care Committee; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Primary outcomes for resuscitation science studies: A consensus statement from the American Heart Association. Circulation. 2011; 124 ( 19 ): 2158 - 2177.
98. Blackwood B, Clarke M, McAuley DF, McGuigan PJ, Marshall JC, Rose L. How outcomes are defi ned in clinical trials of mechanically ventilated adults and children. Am J Respir Crit Care Med. 2014; 189 ( 8 ): 886 - 893.